

Pharma-Bio Serv, Inc.  
Form 8-K  
October 09, 2014

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 9, 2014

Pharma-Bio Serv, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

0-50956                                  20-0653570  
(Commission File Number)          (I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico                                  00646  
(Address of Principal Executive Offices)                                  (Zip Code)

(787) 278-2709  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



Item 8.01. Other Events.

On October 9, 2014, Pharma-Bio Serv, Inc. issued a press release announcing its Collaboration Agreement with Quality Technical Iberica, S.L. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Exhibit Description
-------------	---------------------

99.1	Press Release
------	---------------

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 9, 2014

PHARMA-BIO SERV, INC.

By: /s/ Pedro J. Lasanta  
Pedro J. Lasanta  
Chief Financial Officer and Vice  
President Finance and  
Administration

EXHIBIT INDEX

Exhibit No.	Exhibit Description
----------------	---------------------

99.1	Press Release
------	---------------